Relacorilant

Relacorilant
Clinical data
Trade namesLifyorli
Other namesCORT-125134
AHFS/Drugs.comMonograph
MedlinePlusa626056
License data
Routes of
administration		By mouth
Drug classAntiglucocorticoid
ATC code
  • None
Legal status
Legal status
Identifiers
  • [(4aR)-1-(4-Fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC27H22F4N6O3S
Molar mass586.57 g·mol−1
3D model (JSmol)
  • CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
  • InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
  • Key:WANIDIGFXJFFEL-SANMLTNESA-N

Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Relacorilant is a glucocorticoid receptor antagonist. It is taken by mouth.

The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

Relacorilant was approved for medical use in the United States in March 2026.

Medical uses

Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Adverse effects

The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity. The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

History

Efficacy was evaluated in ROSELLA (NCT05257408), a multi-center, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required. The trial excluded participants who required chronic or frequent use of glucocorticoids. Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.

Society and culture

Relacorilant was approved for medical use in the United States in March 2026.

In September 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Lifyorli, intended for the treatment of adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer. The applicant for this medicinal product is Corcept Therapeutics Netherlands.

Names

Relacorilant is the international nonproprietary name.

Relacorilant is sold under the brand name Lifyorli.

References

  1. 1 2 3 4 5 "Lifyorli- relacorilant kit". DailyMed. 26 March 2026. Retrieved 1 April 2026.
  2. 1 2 3 4 5 6 7 8 9 "FDA approves relacorilant with nab-paclitaxel for platinum-resistant". U.S. Food and Drug Administration (FDA). 25 March 2026. Retrieved 5 April 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ↑ Kansteiner F (25 March 2026). "Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer". Fierce Pharma. Retrieved 26 March 2026.
  4. 1 2 "Lifyorli EPAR". European Medicines Agency (EMA). 18 September 2026. Retrieved 17 October 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
  6. ↑ "FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer" (Press release). Corcept. Retrieved 26 July 2026 – via Business Wire.